कंपनी का अवलोकन
Sonoma Pharmaceuticals, Inc. (SNOA) operates within the healthcare sector, specifically functioning as a drug manufacturer specializing in specialty and generic pharmaceuticals. The enterprise focuses on the development and production of stabilized hypochlorous acid (HOCl) products designed to treat various medical conditions including wound care, eye care, oral and nasal care, podiatry, animal health care, and dermatological issues across the United States, Europe, Asia, Latin America, and international markets. This specialized operational scope positions the firm as a niche player providing therapeutic solutions through its product line, which includes Lumacyn for skin treatments. In terms of corporate scale, the company currently maintains a market capitalization of $3.96M, generates annual revenue of $17.72M, and employs a workforce of 8 individuals. These valuation and revenue figures indicate that Sonoma Pharmaceuticals, Inc. is a micro-cap entity with a relatively small market footprint, suggesting that its business model relies heavily on high-margin niche products rather than broad-scale volume sales typical of larger pharmaceutical conglomerates.
वित्तीय स्वास्थ्य
The company reported revenue of $17.72M over the trailing twelve months, while recording a net income of $-3,370,000 and an EBITDA of $-2,629,000. The significant disparity between the positive revenue figure of $17.72M and the substantial net loss reveals a cost structure characterized by high operating expenses, likely driven by research and development costs, regulatory compliance, and the specialized manufacturing processes required for HOCl products. Free cash flow stands at $-3,573,750, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund operations internally without external capital injections or equity issuance. Analyzing the profitability metrics shows a gross margin of 38.2%, an operating margin of -15.6%, and a profit margin of -19.0%. The positive gross margin suggests that the core cost of goods sold is controlled effectively relative to sales, whereas the negative operating and profit margins demonstrate that overhead costs and selling, general, and administrative expenses are eroding profitability, resulting in an overall loss on sales. Regarding the balance sheet, total cash holdings of $2.56M exceed total debt obligations of $655,000, yet the debt-to-equity ratio of 19.09 reflects a highly leveraged capital structure relative to shareholder equity. Despite the high leverage ratio, the current ratio of 2.88 indicates strong short-term liquidity, suggesting the company possesses sufficient current assets to cover its current liabilities without immediate distress. Return on Equity is reported at -81.2% and Return on Assets at -12.7%, metrics that reveal that management is currently generating negative returns on both shareholder investments and the total asset base due to the company's ongoing losses.
मूल्यांकन आकलन
Valuation metrics for Sonoma Pharmaceuticals, Inc. present a complex picture, with a trailing P/E ratio listed as N/A due to the absence of positive net income, and a forward P/E of -4.09. The negative forward P/E implies that analysts or the market is pricing in a period of continued negative earnings or expects earnings to be negligible in the near future, highlighting the lack of a traditional earnings-based valuation anchor. The price-to-book ratio is 1.15, which indicates that the market values the company slightly above its book value, potentially reflecting expectations of future asset appreciation or intangible value despite current losses. Alternative valuation multiples such as the price-to-sales ratio of 0.22 and an EV/EBITDA of -0.78 suggest the stock is trading at a discount relative to its sales revenue, which is common for early-stage biotech or specialty drug firms awaiting product approval or commercial success. The stock's price volatility is reflected in a 52-week high of $6.92 and a 52-week low of $1.79, with the current trading price situated significantly below the annual peak. The beta value of 1.76 indicates that the stock's price is nearly 1.76 times more volatile than the broader market, meaning it experiences amplified price swings during periods of market turbulence.
Growth & Income
Sonoma Pharmaceuticals, Inc. demonstrates robust revenue expansion with a year-over-year revenue growth rate of 22.0%, whereas earnings growth is listed as N/A due to the company's negative earnings history. The divergence between strong revenue growth and the inability to generate earnings growth implies that top-line sales are increasing, but the cost structure or burn rate is preventing the conversion of these sales into net profit. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all available cash flow to fund operations and growth initiatives rather than distributing income to shareholders. This reinvestment strategy is typical for companies in the development phase or those with negative profitability that prioritize capital allocation toward R&D and market expansion over immediate shareholder returns. The overall growth and income profile is characterized by accelerating sales driven by the adoption of HOCl products, balanced against significant cash consumption and a lack of current income distribution to investors.